Parvane Milad, Nazarian Shahram, Kordbache Emad, Fathi Javad, Minae Mohamad Ebrahim, Ramezani Mohammad Reza
Biology Research Center, Faculty of Basic Sciences, Imam Hossein University, Tehran, Iran.
Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Avicenna J Med Biotechnol. 2022 Oct-Dec;14(4):294-302.
BACKGROUND: Heat Shock Proteins (HSPs) elicit humoral and cellular immune responses. Due to their high sequence homology, they can be developed as a new immunogen for cross prophylactic and vaccination effects against infectious agents such as Enteropathogenic and Enterohemorrhagic (EPEC and EHEC). This study aimed to evaluate the immunogenicity and cross-protective efficacy of rGroEL of () encapsulated in poly lactic-co-glycolic acid (PLGA) nanoparticles against EPEC and EHEC. METHODS: Recombinant GroEL was expressed in () and purified using Ni-NTA affinity chromatography. The protein was encapsulated in PLGA by the double emulsion method, and the nanoparticles were characterized physicochemically. BALB/c mice were immunized, and the efficacy of the protein to elicit immune responses was assessed. RESULTS: Over-expression in led to corresponding 64.5 protein bands in Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE). Non-aggregated nanoparticles had a spherical shape with a mean diameter of 194.3±3 and encapsulation efficiency of 89.5±2.5%. Antibody isotyping revealed that GroEL immunization induced both IgG1 and IgG2a antibodies. Moreover, immunization of the mice with recombinant GroEL protein conferred 80 and 60% protection against lethal infections by EPEC and EHEC, respectively. Furthermore, organ burden studies revealed a significant reduction in infection in the immunized mice compared to the non-immunized ones. Passive immunization with anti-GroEL sera also protected 50% of the mice against the lethal doses of EHEC and EPEC strains. CONCLUSION: The findings indicated that immunization of the mice with recombinant GroEL of elicited cross-protection against other bacterial infections. This represented the immense potential of GroEL to be developed as a single vaccine against multiple pathogens.
Avicenna J Med Biotechnol. 2022
Immunol Cell Biol. 2013-10-22
J Pharm Investig. 2021
Nat Rev Microbiol. 2021-5
Vaccines (Basel). 2020-12-17